Related Experiment Video
Updated: Sep 9, 2025
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
Published on: July 10, 2018
3,6'-Disinapoyl sucrose modulates GALE-mediated metabolic reprogramming to alleviate asthmatic airway inflammation
Haisong Jiang1, Ningpo Ding2, Zongqi Wang2
1Department of Anesthesiology, Yanbian University Medical College, Yanji 133002, PR China; Jilin Key Laboratory for Immune and Targeting Research on Common Allergic Diseases, Yanbian University, Yanji 133002, PR China.
Background:
Asthma is a heterogeneous disease characterized by chronic airway inflammation and metabolic dysregulation. Recent studies highlight the role of glycolysis and oxidative phosphorylation (OXPHOS) imbalance in asthma pathogenesis, yet the underlying molecular mechanisms remain unclear. UDP-galactose-4-epimerase (GALE), a key enzyme in galactose metabolism, has not been previously explored in asthma.
Purpose:
This study aimed to identify asthma-associated metabolic genes and investigate the therapeutic potential of 3,6'-Disinapoyl Sucrose (DISS), a natural compound, in modulating GALE-mediated metabolic reprogramming.
Results:
Weighted Gene Co-Expression Network Analysis (WGCNA) of bronchial epithelial datasets (GSE43696, GSE147878, GSE143303) identified 475 asthma-associated genes enriched in carbohydrate metabolism. Intersection with glycolysis/OXPHOS hallmark genes revealed GALE as a key candidate, validated by machine learning (SVM-RFE, RF, LASSO) and multi-dataset analysis. GALE expression correlated with severe and neutrophilic asthma subtypes. Virtual screening prioritized DISS as a GALE inhibitor (-14.91 kcal/mol), which suppressed glycolysis (reduced ECAR, PFK, PKM, LDHA), restored redox balance (increased SOD/CAT, decreased MDA), and mitigated mitochondrial dysfunction (restored ΔΨm, reduced mtROS) in HDM-stimulated BEAS-2B cells. In vivo, DISS attenuated airway inflammation (reduced IL-4, IL-5, IL-13, IgE), mucus hypersecretion, and pathological remodeling in HDM-induced asthmatic mice.
Conclusion:
GALE-driven metabolic reprogramming is a novel mechanism in asthma progression. DISS alleviates airway inflammation by targeting GALE, normalizing glycolysis, and reducing oxidative stress, offering a promising therapeutic strategy.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...